Since CTR9 depletion generates therapeutic vulnerability to pharmacological inhibition of PRC2, the CTR9 expression levels may be used as a biomarker for predicting PRC2 dependency and EZH2 inhibitor sensitivity in broad cancer types. The gene discussed is EZH2; the disease is cancer.